Biocytogen

🚀 Meet Us @ CBA-GP Biomedical Science Symposium 2025! We’re excited to showcase our innovations at the CBA-GP Biomedical Science Symposium on February 8th in Philadelphia! This premier event connects biotech leaders, investors, and industry experts, fostering collaboration and scientific breakthroughs. Hosted by CBA-GP, the symposium features top academics, entrepreneurs, and executives from leading pharma companies like J&J, Merck, GSK, and BMS. Join us at the Baldwin School for a day of cutting-edge science and networking! 📅Date: February 8th 📍Location: The Baldwin School. 701 W Montgomery Ave, Bryn Mawr, PA 19010 #Biocytogen #CBAGP #BiomedicalSymposium #Biotech #Pharma #Innovation 🚀

🧬 Advancing NK Cell-Dependent Therapeutics with B-NDG hIL15 Mice! 🔬 Highly immunodeficient mouse models enable human immune system reconstitution, facilitating research on immune function, therapeutic efficacy, and disease modeling. However, while these models effectively reconstitute human T cells, the absence of human IL15—a critical cytokine for NK cell maturation—hinders human NK cell reconstitution, limiting research on NK-dependent immunotherapies. To address this, Biocytogen developed B-NDG hIL15 mice, an IL15-humanized model based on our highly immunodeficient B-NDG mice. B-NDG hIL15 expresses human IL15 but not mouse IL15, significantly enhancing human NK cell reconstitution. The reconstituted mice also support CDX and PDX models and have been used to evaluate antibodies such as anti-human CLDN18.2 (Zolbetuximab) and CD3×HER2 bispecific antibodies, demonstrating their antitumor activity. Ready to accelerate your NK cell studies? Contact us to learn more! 🚀 Read more: https://lnkd.in/e7NVEQpk #Immunotherapy #NKCells #BNDGhIL15 #PreclinicalResearch #Oncology #Biocytogen #CDX #PDX #AntibodyDiscovery #Innovation #Reconstitution #IL15 #ImmuneReconstitution

🔬 Revolutionizing Nanobody Discovery with RenNano Mice! 🚀 VHHs (~12-15 kDa) are single antigen-binding domains known for their exceptional tumor penetration and ability to cross the blood-brain barrier, making them powerful tools for both diagnostics and therapeutics. Biocytogen’s RenNano mice provide a fully human, heavy chain-only platform for VHH discovery, generating high-affinity, highly specific VHHs with strong biological activity that support diverse drug modalities such as bispecific/multispecific antibodies, ADCs, and cell therapies. With the Nano 100 Project, launched in February 2023, Biocytogen is advancing fully human therapeutic VHHs targeting 100+ antigens. We are actively seeking global partners for VHH-based therapeutics, including cell therapies, BBB shuttles, bispecific/multispecific antibodies, ADCs, and RACs.  Let’s collaborate to develop first-in-class and best-in-class treatments! 📩 Contact us to explore co-development and licensing opportunities. #Biocytogen #RenNano #VHH #Nanobody #AntibodyDiscovery #Bispecifics #ADCs #CellTherapy #Biopharma #Innovation #DrugDevelopment 🚀

⏰ Next Week! Webinar on Expanding Tumor Antigen Targeting with TCR-Mimic Antibodies 🌟 Overcoming the limits of traditional antibody therapies starts here. Learn how Biocytogen’s RenMice platform is unlocking intracellular tumor antigen targeting with TCR-mimic antibodies! 📅 Date & Time: Wed, Feb 12, 11:00 AM EST 🎙️ Speaker: Dr. Wanbo Tang 👉 Register now: https://lnkd.in/e9nXTUPV 🎯 What You’ll Learn: - Limitations of traditional antibody therapies. - Biocytogen’s TCR-mimic platform for generating fully human TCRm antibodies. - How TCRm antibodies expand targetable antigens in cancer immunotherapy. - Case studies showcasing the applications of TCRm antibodies.

🚀 Fresh Start at Biocytogen! 🚀 As January comes to a close, now’s the perfect time to turn career goals into reality! Whether you're a recent graduate eager to jumpstart your journey or a seasoned professional ready for your next big move, Biocytogen has exciting opportunities waiting for you. ✨ Join our dynamic Boston team and be part of groundbreaking innovations shaping the future of healthcare! 📩 Ready to make an impact? Reach out to hr@biocytogen.com to explore open positions. Let’s make 2025 a year of bold steps and big wins—together! 💙 Explore Biocytogen Careers: https://lnkd.in/eDb66tP ➡Scientist for Content Marketing: https://lnkd.in/evg5jCiH ➡ Scientist/Sr. Scientist-Preclinical Antibody Drug Development: https://lnkd.in/eTTnvQXb ➡Marketing Intern: https://lnkd.in/ehH5adHM ➡Husbandry Technician: https://lnkd.in/emUi5faM ➡Gene Targeting Project Manager/ Scientist: https://lnkd.in/e_RvYevB ➡ Scientist/Sr. Scientist for in vitro Pharmacology: https://lnkd.in/e2V8YaWT #JoinUs #BiotechJobs #Innovation #BostonJobs #CareerOpportunity #Biocytogen #Hiring

🧬 Empowering IBD Therapies: Biocytogen's Humanized Mice Targeting the TL1A Pathway🚀 TL1A therapies are making waves in the fight against inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis! Several TL1A inhibitors—including monoclonal and bispecific antibodies like duvakitug, tulisokibart, PF-07261271, and FG-M701—are under development to address unmet needs in IBD. TL1A plays a crucial role in immune regulation by activating pathways involved in cell proliferation, apoptosis, and cytokine production, offering promising therapeutic opportunities. At Biocytogen, we’re advancing IBD research with our humanized mouse models targeting TL1A signaling pathways and robust IBD models developed using diverse induction methods across genetic backgrounds. These models support preclinical research and efficacy evaluation, accelerating innovation in IBD therapies. Contact us to learn more about how our models can drive your research forward! 🌍✨ Read more about TL1A: https://lnkd.in/e-QYNRim #Biocytogen #TL1A #IBD #InflammatoryBowelDisease #IBDResearch #HumanizedMice #DrugDiscovery #InnovationInBiotech #AutoimmuneTherapies #CrohnsDisease #UlcerativeColitis

Innovating Monkeypox Virus Therapies with Antibodies from RenMab® Mice The global impact of the monkeypox virus (MPXV) continues to escalate, with over 100,000 reported cases. Despite the approval of two vaccines, a critical shortage persists, and no FDA-approved treatment is currently available. The development of new therapies is urgently needed. Biocytogen is tackling this challenge head-on with its RenMab® mice. Using rapid screening with Beacon® technology, we’ve developed over 100 candidate antibody sequences targeting critical proteins of the monkeypox virus, such as B6 and A35. These antibodies demonstrate effective neutralization of MPXV in vitro, offering hope for novel treatments. 🌟 Contact us today to learn more about our MPXV antibodies, explore licensing or co-development opportunities, and access the latest validation data! #Monkeypox #BiotechInnovation #AntibodyTherapy #RenMab #InfectiousDiseases #ViralTherapeutics #Biocytogen #CoDevelopment #PublicHealth 🌍💉

#BehindTheScene🚴♂️ Meet Nishit: Foodie, Biker, and Innovator at Biocytogen! 🍕🔬 Nishit Singh’s journey is as vibrant as his love for food and biking! Whether savoring Boston’s culinary delights, indulging in his favorite Indian dishes, or cruising along the scenic Charles River, Nishit brings an infectious energy to every aspect of his life. His passion for exploration fuels both his personal adventures and his professional drive at Biocytogen. From tackling complex experiments to collaborating with senior scientists, Nishit’s dedication and zest for life shine through in everything he does. At Biocytogen, Nishit thrives by combining curiosity, creativity, and hard-earned skills. From mastering advanced techniques like flow cytometry and ELISA to balancing multiple projects with precision, his career is built on a solid foundation of time management and collaboration. Nishit’s advice? Stay curious. Whether you’re analyzing unexpected data or diving into the latest research, a curious mindset can transform challenges into opportunities and keep the magic of discovery alive. Read more: https://lnkd.in/eTBSQRqf #Biocytogen #BiotechInnovators #FoodieScientist #CareerJourney #ScientificDiscovery #InnovationInBiotech #StayCurious

2024 Biopharma M&A Trends: Deals and Big Moves 🚀💊 In 2024, the biopharma M&A landscape remained active, with a strong emphasis on immunology and oncology. Here are the key highlights from the top 10 deals: - Novo Holdings made a bold $16.5B move to acquire Catalent, marking the year’s biggest deal by value. - Sanofi streamlined its focus by selling a 50% stake in Opella for €8B to CD&R. - Vertex added Alpine Immune Sciences for $4.9B, expanding its autoimmune pipeline. - Gilead Sciences acquired CymaBay Therapeutics for $4.3B, leveraging its liver disease expertise to launch Livdelzi, a promising treatment for primary biliary cholangitis. - Eli Lilly secured Morphic Therapeutics for $3.2B, pushing its IBD treatments forward. - Merck acquired EyeBio for $3B, diversifying into eye diseases with promising candidates. - Roquette acquired International Flavors & Fragrances' Pharma Solutions for $2.85B, boosting its pharma excipients portfolio and health and nutrition presence. - Novartis and MorphoSys sealed a €2.7B deal to advance oncology therapies. - Lundbeck acquired Longboard Pharmaceuticals for $2.5B, targeting epilepsy with promising treatments. - Ono Pharmaceutical bought Deciphera Pharmaceuticals for $2.4B to boost its oncology portfolio. The trend of 2024 Biopharma M&A focused on innovative treatments and strategic growth. Stay tuned for more impactful M&A as we head into 2025! 🔬 #Biopharma #MergersAndAcquisitions #Oncology #Immunology #DrugDevelopment #InnovativeTreatments #Biotech #PharmaDeals #2024M&A